LAPC4

LAPC4是在肿瘤学领域中常用的人类前列腺癌细胞系，最初是从一名男性前列腺癌患者的淋巴结中转移，并且将其异种移植到患有严重复合型免疫缺乏症的小鼠中，然后收集及铺设在培养基中，则可以作为永生化的前列腺癌细胞系进行繁殖^[1]^[2]^[3]。

特征[编辑]

LAPC4细胞的倍增时间约为72小时。LAPC4是具有雄激素受体和前列腺特异抗原高度表达的低粘附性上皮细胞系，其与对雄激素受体呈阳性反应的前列腺癌细胞系LNCaP和VCaP等常用细胞系不同，具有较高的Keratin 5（英语：Keratin 5）（即基础标记物）及腔标记物Keratin 8（英语：Keratin 8）与Keratin 18（英语：Keratin 18）的表达^[4]。

参考资料[编辑]

^ Klein, KA; Reiter, RE; Redula, J; Moradi, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.. Nature medicine. 1997-04, 3 (4): 402–8 [2020-01-03]. PMID 9095173. doi:10.1038/nm0497-402. （原始内容存档于2020-01-03）.
^ Russell, Pamela J.; Kingsley, Elizabeth A. Chapter 2: Human Prostate Cancer Cell Lines (PDF). Russell, Pamela J.; Jackson, Paul; Kingsley, Elizabeth A. (编). Prostate cancer methods and protocols. Totowa, N.J.: Humana Press. 2003: 21–39 [2020-01-03]. ISBN 978-1-59259-372-9. （原始内容存档 (PDF)于2020-07-10）.
^ Garcia, RR; Masoodi, KZ; Pascal, LE; Nelson, JB; Wang, Z. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.. American journal of clinical and experimental urology. 2014, 2 (1): 82–91 [2020-01-03]. PMID 25374909. （原始内容存档于2020-01-03）.
^ van Bokhoven, A; Varella-Garcia, M; Korch, C; Johannes, WU; Smith, EE; Miller, HL; Nordeen, SK; Miller, GJ; Lucia, MS. Molecular characterization of human prostate carcinoma cell lines.. The Prostate. 2003-11-01, 57 (3): 205–25 [2020-01-03]. PMID 14518029. doi:10.1002/pros.10290. （原始内容存档于2020-01-03）.

外部链接[编辑]

Cellosaurus entry for LAPC4 （页面存档备份，存于互联网档案馆）

[1] Klein, KA; Reiter, RE; Redula, J; Moradi, H; Zhu, XL; Brothman, AR; Lamb, DJ; Marcelli, M; Belldegrun, A; Witte, ON; Sawyers, CL. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.. Nature medicine. 1997-04, 3 (4): 402–8 [2020-01-03]. PMID 9095173. doi:10.1038/nm0497-402. （原始内容存档于2020-01-03）.

[Russell-2] Russell, Pamela J.; Kingsley, Elizabeth A. Chapter 2: Human Prostate Cancer Cell Lines (PDF). Russell, Pamela J.; Jackson, Paul; Kingsley, Elizabeth A. (编). Prostate cancer methods and protocols. Totowa, N.J.: Humana Press. 2003: 21–39 [2020-01-03]. ISBN 978-1-59259-372-9. （原始内容存档 (PDF)于2020-07-10）.

[3] Garcia, RR; Masoodi, KZ; Pascal, LE; Nelson, JB; Wang, Z. Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride.. American journal of clinical and experimental urology. 2014, 2 (1): 82–91 [2020-01-03]. PMID 25374909. （原始内容存档于2020-01-03）.

[4] van Bokhoven, A; Varella-Garcia, M; Korch, C; Johannes, WU; Smith, EE; Miller, HL; Nordeen, SK; Miller, GJ; Lucia, MS. Molecular characterization of human prostate carcinoma cell lines.. The Prostate. 2003-11-01, 57 (3): 205–25 [2020-01-03]. PMID 14518029. doi:10.1002/pros.10290. （原始内容存档于2020-01-03）.

[1]

[2]

[3]

[4]